Investigation of Underlying Biological Association and Targets between Rejection of Renal Transplant and Renal Cancer DOI Creative Commons
Yinwei Chen, Zhanpeng Liu, Qian Yu

et al.

International Journal of Genomics, Journal Year: 2023, Volume and Issue: 2023, P. 1 - 19

Published: May 23, 2023

Post-renal transplant patients have a high likelihood of developing renal cancer. However, the underlying biological mechanisms behind development cancer in post-kidney remain to be elucidated. Therefore, this study aimed investigate mechanism cell carcinoma post-renal patients.Next-generation sequencing data and corresponding clinical information with clear (ccRCC) were obtained from The Cancer Genome Atlas Program (TCGA) database. microarray kidney or without rejection response was Gene Expression Omnibus (GEO) In addition, statistical analysis conducted R software.We identified 55 upregulated genes GEO datasets (GSE48581, GSE36059, GSE98320). Furthermore, we bioinformatics analyses, which showed that all these ccRCC tissue. Moreover, prognosis model constructed based on four rejection-related genes, including PLAC8, CSTA, AIM2, LYZ. excellent performance prediction cohort. machine learning algorithms 19 involved occurrence. Finally, PLAC8 selected for further research, its role.In all, our provides novel insight into transition Meanwhile, could potential biomarker diagnosis patients.

Language: Английский

Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Molecular Basis and Rationale for Their Use in Clinical Practice DOI Creative Commons
Francesco Lasorsa,

Nicola Antonio di Meo,

Monica Rutigliano

et al.

Biomedicines, Journal Year: 2023, Volume and Issue: 11(4), P. 1071 - 1071

Published: April 2, 2023

Renal cell carcinoma (RCC) is the seventh most common cancer in men and ninth women worldwide. There plenty of evidence about role immune system surveillance against tumors. Thanks to a better understanding immunosurveillance mechanisms, immunotherapy has been introduced as promising treatment recent years. long thought chemoresistant but highly immunogenic. Considering that up 30% patients present metastatic disease at diagnosis, around 20–30% undergoing surgery will suffer recurrence, we need identify novel therapeutic targets. The introduction checkpoint inhibitors (ICIs) clinical management RCC revolutionized approach this tumor. Several trials have shown therapy with ICIs combination or tyrosine kinase inhibitor very good response rate. In review article summarize mechanisms immunity modulation checkpoints discuss potential strategies renal treatment.

Language: Английский

Citations

75
Cellular and Molecular Players in the Tumor Microenvironment of Renal Cell Carcinoma DOI Open Access
Francesco Lasorsa,

Monica Rutigliano,

Martina Milella

et al.

Journal of Clinical Medicine, Journal Year: 2023, Volume and Issue: 12(12), P. 3888 - 3888

Published: June 7, 2023

Globally, clear-cell renal cell carcinoma (ccRCC) represents the most prevalent type of kidney cancer. Surgery plays a key role in treatment this cancer, although one third patients are diagnosed with metastatic ccRCC and about 25% will develop recurrence after nephrectomy curative intent. Molecular-target-based agents, such as tyrosine kinase inhibitors (TKIs) immune checkpoint (ICIs), recommended for advanced cancers. In addition to cancer cells, tumor microenvironment (TME) includes non-malignant types embedded an altered extracellular matrix (ECM). The evidence confirms that interactions among cells TME elements exist thought play crucial roles development making them promising therapeutic targets. TME, unfavorable pH, waste product accumulation, competition nutrients between may be regarded further possible mechanisms escape. To enhance immunotherapies reduce resistance, it is first understand how work interact other cancer-associated complex microenvironment.

Language: Английский

Citations

71
The evolving management of small renal masses DOI
Yuzhi Wang, Mohit Butaney,

Samantha Wilder

et al.

Nature Reviews Urology, Journal Year: 2024, Volume and Issue: 21(7), P. 406 - 421

Published: Feb. 16, 2024

Language: Английский

Citations

9
Unlocking Precision Medicine: Liquid Biopsy Advancements in Renal Cancer Detection and Monitoring DOI Open Access
Felice Crocetto,

Alfonso Falcone,

Benito Fabio Mirto

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(7), P. 3867 - 3867

Published: March 30, 2024

Renal cell carcinoma (RCC) remains a formidable diagnostic challenge, especially in the context of small renal masses. The quest for non-invasive screening tools and biomarkers has steered research towards liquid biopsy, focusing on microRNAs (miRNAs), exosomes, circulating tumor cells (CTCs). MiRNAs, non-coding RNAs, exhibit notable dysregulation RCC, offering promising avenues diagnosis prognosis. Studies underscore their potential across various biofluids, including plasma, serum, urine, RCC detection subtype characterization. Encouraging miRNA signatures show correlations with overall survival, indicative future relevance management. Exosomes, diverse molecular cargo, miRNAs, emerge as enticing biomarkers, while CTCs, emanating from primary tumors into bloodstream, provide valuable insights cancer progression. Despite these advancements, clinical translation necessitates further validation standardization, encompassing larger-scale studies robust evidence generation. Currently lacking approved assays cancer, applications biopsy follow-up care, treatment selection, outcome prediction patients are profound. This review aims to discuss highlight recent advancements exploring strengths weaknesses comprehensive management this disease.

Language: Английский

Citations

9
Comparative Diagnostic Performance of Color Doppler Flow Imaging, MicroFlow Imaging and Contrast-enhanced Ultrasound in Solid Renal Tumors DOI
Chunxiang Li,

Lisha Qi,

Changming Geng

et al.

Academic Radiology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

Citations

1
Targeting carbonic anhydrases for the management of hypoxic metastatic tumors DOI
Claudiu T. Supuran

Expert Opinion on Therapeutic Patents, Journal Year: 2023, Volume and Issue: 33(11), P. 701 - 720

Published: Aug. 7, 2023

ABSTRACTIntroduction Several isoforms of the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1) are connected with tumorigenesis. Hypoxic tumors overexpress CA IX and XII as a consequence HIF activation cascade, being involved in pH regulation, metabolism, metastases formation. Other (CA I, II, III, IV) were also reported to be present some tumors.Areas Covered Some biomarkers for disease progression or response therapy. Inhibitors, antibodies, other procedures targeting these enzymes treatment tumors/metastases discussed. Sulfonamides coumarins represent most investigated classes inhibitors, but carboxylates, selenium, tellurium-containing inhibitors investigated. Hybrid drugs antitumor agents multitargeted therapy reported.Expert opinion Targeting CAs solid hematological selective, targeted is validated approach, which has been consolidated last years. A host new preclinical data several clinical trials antibodies small-molecule ongoing, large number chemotypes/procedures discovered effective, may lead breakthrough this therapeutic area. The scientific/patent literature searched on PubMed, ScienceDirect, Espacenet, PatentGuru, from 2018 2023.KEYWORDS: anhydraseanticancer drugshypoxic tumorinhibitorssulfonamidescoumarinsantibodieshybrid Article highlights hCA expressed hypoxic tumor cells, promoting growth metastasis formation tumorsIsoforms such IV found many types, considered novel targetsExosomes patients enriched cancer-associated CAs, IXA available, chemotypes periodSulfonamides prevalently isoform-selective compounds available dateNovel chemotypes, incorporating selenium tellurium obtained, contribute effects by additional mechanisms actionHybrid (estrogen receptor modulators; vascular endothelial factor 2 antagonists; H2S releasing agents; signal transducer transcriptional activator 3 mono- triterpenes) possess enhanced antitumor/antimetastatic effectsSeveral MAbs one sulfonamide inhibitor (SLC-0111) under evaluation various phases development.Declaration interestsClaudiu T Supuran declares conflict interest discoverer SLC-0111 phase Ib/II trials. author no relevant affiliations financial involvement any organization entity subject matter materials discussed manuscript apart those disclosed.Reviewer disclosuresPeer reviewers have relationships disclose.Additional informationFundingThis paper was not funded.

Language: Английский

Citations

22
CECT-Based Radiomic Nomogram of Different Machine Learning Models for Differentiating Malignant and Benign Solid-Containing Renal Masses DOI Creative Commons
Qian Lu, Bo Fu, Hong He

et al.

Journal of Multidisciplinary Healthcare, Journal Year: 2025, Volume and Issue: Volume 18, P. 421 - 433

Published: Jan. 1, 2025

This study aimed to explore the value of a radiomic nomogram based on contrast-enhanced computed tomography (CECT) for differentiating benign and malignant solid-containing renal masses. A total 122 patients with pathologically confirmed (n=47) or (n=75) masses were enrolled in this study. Radiomic features extracted from arterial, venous delayed phases further analysed by dimensionality reduction selection. Four mainstream machine learning algorithm training models, namely, support vector (SVM), k-nearest neighbour (kNN), light gradient boosting (LightGBM) logistic regression (LR), constructed determine best classifier model. Univariate multivariate analyses used clinical characteristics constructing The signatures integrated construct combined Receiver operating characteristic (ROC) curves area under curve (AUC) evaluate performance nomogram, signature, Thirteen selected development signature. Among various LR model demonstrated superior predictive efficiency robustness, yielding an AUC 0.952 cohort 0.887 test cohort. was 0.854 0.747 Furthermore, which incorporated sex, age, alcohol consumption history, exhibited excellent discriminative performance, 0.973 0.900 CECT offers promising noninvasive approach distinguishing solid tool can be guide treatment strategies effectively provide valuable insights clinicians.

Language: Английский

Citations

0
Foundation Model and Radiomics-Based Quantitative Characterization of Perirenal Fat in Renal Cell Carcinoma Surgery DOI
Haonan Mei, Hui Chen, Qingyuan Zheng

et al.

Academic Radiology, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Language: Английский

Citations

0
FABP4-mediated ERK phosphorylation promotes renal cancer cell migration DOI Creative Commons
Evelina La Civita,

Rosa Sirica,

Felice Crocetto

et al.

BMC Cancer, Journal Year: 2025, Volume and Issue: 25(1)

Published: March 30, 2025

Clear cell Carcinoma (ccRCC) is the most common and lethal subtype among renal cancers. In present study we investigated potential role of fatty acid-binding protein 4 (FABP4), also known as adipocyte FABP (A-FABP) or aP2 on ccRCC progression. Firstly, found that FABP4 median serum levels were significantly higher in patients compared to HD. Based this result evaluate whether plays a cancer malignant phenotype, analyzed proliferation migration 786-O ACHN lines using recombinant FABP4. We increased migration, whereas it had no significant effect proliferation. As mainly expressed by adipocytes, measured conditioned media (Ad-CM) showing Ad-CM from (Ad-CM ccRCC) mean values obtained Healthy Donors (HD). To assess effects adipocyte-released FABP-4, phenotype evaluated HD alone combination with inhibitor BMS309403. Our results showed enhanced ACHN, but not motility both was partially reverted BMS309403 lines. Moreover, lines, associated an ERK phosphorylation. Collectively these data support progression its use noninvasive biomarker therapeutic target for ccRCC.

Language: Английский

Citations

0
The cutting edge: Promising oncology radiotracers in clinical development DOI
Jorge D. Oldan, Martin G. Pomper, Rudolf A. Werner

et al.

Diagnostic and Interventional Imaging, Journal Year: 2024, Volume and Issue: 105(10), P. 400 - 406

Published: May 14, 2024

Language: Английский

Citations

3